Acta Veterinaria et Zootechnica Sinica ›› 2025, Vol. 56 ›› Issue (1): 343-352.doi: 10.11843/j.issn.0366-6964.2025.01.032

• Preventive Veterinary Medicine • Previous Articles     Next Articles

Prokaryotic Expression and Immunogenicity Analysis of OmpD and LppB of Actinobacillus pleuropneumoniae

ZENG Yan1(), OU Xianglong1, YAN Xiaoyang1, LIU Can1, LIAO Yonghong1,2,*()   

  1. 1. College of Veterinary Medicine, Southwest University, Chongqing 402460, China
    2. National Center of Technology Innovation for Pigs, Chongqing 402460, China
  • Received:2024-01-26 Online:2025-01-23 Published:2025-01-18
  • Contact: LIAO Yonghong E-mail:2685343085@qq.com;yonghongliao@swu.edu.cn

Abstract:

This study evaluated the immunogenicity and protective efficacy of OmpD and LppB proteins from Actinobacillus pleuropneumoniae. Homology analysis revealed that all 19 serotypes of APP have ompD and lppB genes, with amino acid sequence identities of 98.2%-100% and 99.3%-100%, respectively. Recombinant OmpD (rOmpD) and LppB (rLppB) proteins from serotype 1 were expressed and purified using engineered E. coli and subjected to immunogenicity analysis. The results showed that both proteins were effectively expressed and exhibited obvious reactivity with swine convalescent serum. Mice immunized with rOmpD or rLppB leaded to significantly elevated ELISA antibody titers and protection rates of 70%-80% against challenge with prevalent serotype 1 and 7 strains. Further, an oil emulsion containing rOmpD and rLppB was prepared, and immunization of piglets elicited significantly elevated ELISA antibody titers and conferred partial protection and cross-protection against serotype 1 and 7 challenge. However, complete protection against infection and death was not achieved. These findings suggest that OmpD and LppB are promising candidates for subunit vaccine development against Actinobacillus pleuropneumoniae, and provide valuable data for the further development of vaccines with cross-protective efficacy.

Key words: Actinobacillus pleuropneumoniae, OmpD, LppB, immunogenicity, efficacy

CLC Number: